RGO-Based Memristive Sensor for Rapid Hydrogen Detection at Room-Temperature

In recent years, there has been a growing interest in investigating the potential of emerging memristor (MR) devices for gas sensing applications, particularly at room temperature. This article reports on a planar Au/reduced graphene oxide (rGO)/Au memristive hydrogen sensor, fabricated on a cost-effective cyclic olefin copolymer (COC) substrate, and utilizing the rGO green carbon material as its active sensing element. The sensor's performance is evaluated using two different testing modes: conventional chemiresistive testing under a constant voltage bias (CVB) and voltage pulse (VP) modes. The CVB mode demonstrates high repeatability, selectivity, response time, and recovery time, indicating the sensor's reliable gas sensing capabilities. In addition, the VP mode significantly enhances the sensor's relative percentage response, indicating its potential for improved gas sensing performance. To optimize the sensor's response, the impact of hydrogen exposure on the MR resistive switching is studied, revealing that the effect is contingent on the VP amplitude. Specifically, gas-enhanced resistive switching is achieved at lower voltage levels, whereas at higher voltage levels, gas exposure slows down the rate of resistive switching. Consequently, voltage-pulse testing is conducted at two voltage magnitudes, low (2.5 V) and high (4.5 V), and the sensor's response is enhanced from 0.5% under CVB mode to 786% under VP mode.Green Open Access added to TU Delft Institutional Repository ‘You share, we take care!’ – Taverne project https://www.openaccess.nl/en/you-share-we-take-care Otherwise as indicated in the copyright section: the publisher is the copyright holder of this work and the author uses the Dutch legislation to make this work public.Computer Engineerin

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics